Six biotechnology startups are merging into a new skin drug developer called Alys Pharmaceuticals, which launched on Monday with $100 million from European life sciences investment firm Medicxi.
Alys was formed out of the merger of a group of biotechs hatched in recent years by Medicxi: Granular Therapeutics, Aldena Therapeutics, Nira Biosciences, Graegis Pharmaceuticals and Vimela Therapeutics. They’ve been combined to create a larger company with a broad pipeline of experimental dermatology medicines.
